Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo to Present at the 2022 Jefferies Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present...
May 18, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2,...
May 17, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present...
May 05, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion deficiency type II (LAD II)Executed workforce...
March 08, 2022 07:00 ET | Source: Avalo Therapeutics

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
March 02, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectivelyAnnounced plans to initiate a Phase 2 randomized, double-blind, placebo-controlled trial...
February 17, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo Therapeutics Announces Leadership Transition

Promotes Dr. Garry Neil to Chief Executive OfficerPromotes Chris Sullivan to Chief Financial Officer WAYNE, Pa. and ROCKVILLE, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc....
February 07, 2022 16:01 ET | Source: Avalo Therapeutics

Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference

WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
January 10, 2022 19:59 ET | Source: Avalo Therapeutics

Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer

WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company that...
January 06, 2022 07:30 ET | Source: Avalo Therapeutics

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseasesEfficacy signal demonstrated in heavily...